KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Equity Ratio (2016 - 2026)

Pacira BioSciences has reported Equity Ratio over the past 17 years, most recently at 0.54 for Q1 2026.

  • For Q1 2026, Equity Ratio rose 7.51% year-over-year to 0.54; the TTM value through Mar 2026 reached 0.54, up 7.51%, while the annual FY2025 figure was 0.55, 9.37% up from the prior year.
  • Equity Ratio for Q1 2026 was 0.54 at Pacira BioSciences, down from 0.55 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.56 in Q1 2024 and troughed at 0.38 in Q1 2022.
  • A 5-year average of 0.5 and a median of 0.5 in 2023 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: decreased 25.78% in 2022 and later surged 34.39% in 2023.
  • Year by year, Equity Ratio stood at 0.46 in 2022, then increased by 19.89% to 0.55 in 2023, then decreased by 9.35% to 0.5 in 2024, then rose by 9.37% to 0.55 in 2025, then fell by 1.26% to 0.54 in 2026.
  • Business Quant data shows Equity Ratio for PCRX at 0.54 in Q1 2026, 0.55 in Q4 2025, and 0.56 in Q3 2025.